About

A pioneering initiative in AI-driven discovery

The Consortium for Biomedical Research and Artificial Intelligence in Neurodegeneration (C-BRAIN) is a bold, multi-sector initiative whose mission is to redefine how biomedical research is conducted through the power of artificial intelligence (AI). Backed by some of the most innovative and influential organizations in academia, industry, and philanthropy, C-BRAIN is building a first-of-its-kind AI-based Biomedical Research Scientist: a dynamic, scientist-in-the-loop platform designed to accelerate breakthroughs in neuroscience, brain aging, and neurodegenerative disease research. This is a well-resourced, high-impact effort with the potential to transform the field.

Trend line

Revolutionize

data analysis by applying human-augmented AI

Trend line

Accelerate

impactful discoveries through collaboration

Trend line

Deliver

an open-source model to benefit the scientific community and enhance patient outcomes

Urgent challenge,
opportune moment

Register to receive updates »

C-BRAIN will develop an “AI Biomedical Research Scientist” to assist human researchers by synthesizing data, generating hypotheses, and designing experiments. We aim to transform biomedical research by integrating across the discovery lifecycle.

Powered by collaboration among nearly 60 organizations worldwide:

  • Led by researchers from academia, industry, and philanthropy, including WashU Medicine
  • Tech industry giants
  • Leading biopharma and biotech companies
  • Philanthropic and non-profit organizations
  • Government agencies

Scalable: An initial focus on Alzheimer’s will expand to other neurodegenerative diseases

Human Collaboration: Designed to work alongside researchers, bridging the gap between data and discovery

Expertise: Academic/industry collaboration to ensure AI tools meet scientific needs

AI Training: Reading scientific literature, integrating complex datasets, generating new hypotheses, and designing experiments

Breadth and depth of data, including proprietary and unpublished datasets from industry — all within a secure, ethical, and coordinated framework

Focus: Targeted at biomedical research, not clinical applications or drug discovery